CLARAMETYX BIOSCIENCES, INC

Columbus, OH · Founded 2020 · Biotech · Private

Immune-enabling therapeutics targeting bacterial biofilms in chronic respiratory diseases

Claim this profile

Follows are private to you and power your alerts

Updated · clarametyx.com

Sector
Biotech
Headquarters
Columbus, OH
Founded
2020
Latest Form D
$27.5M, Jan 2024
Total capital
$29.5M
Federal grants
$2M
1 award · 2022
Rank in peer group#51 of 326
Private capital raised
$27.5M
1 Form D · last Jan 2024
33 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
None on recordNo USPTO grants. Applications publish after 18 months.

Capital timeline

202220232024FEDERAL ↑EQUITY ↓Cumulative $29.5M$2M1st Form D$27.5M
202220232024FEDERAL ↑EQUITY ↓Cumulative $29.5M$2M1st Form D$27.5M

Latest events

  • Private capital raisedForm D · SEC · 1st filing$27.5M
  • Federal grantHealth and Human S · Phase II · Development of a Multi-species Vaccine for Prevention of Bacterial Otitis Media$2M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Federal first

25months

from CLARAMETYX BIOSCIENCES, INC’s first federal award to its first private round.

First federal award · Jan 2022
Health and Human S · $2M
First Form D · Jan 2024
$27.5M · 1st Form D
Awards before first raise
1 award

An association in public records, not a cause or a prediction.

Standing among 326 peers

Line = median

Biotech · Molecule

  • Federal grants#51 · top 16%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings
  • Chuck G. BramlageDirectorNamed in SEC Form D filings
  • David RichardsExecutive OfficerNamed in SEC Form D filings
  • Larry G. EdwardsDirectorNamed in SEC Form D filings
  • Michael G. LaymanDirectorNamed in SEC Form D filings
  • Michael Triplett IIDirectorNamed in SEC Form D filings
  • Peter G. KleinhenzDirectorNamed in SEC Form D filings
Show all 8 people
  • Wayne G. EmbreeDirectorNamed in SEC Form D filings
  • William G. BaumelDirectorNamed in SEC Form D filings

What it has protected

No granted patents are on record.

USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.

Checked: USPTO granted patents and published applications · Oct 23, 2026

  • IMMUDX, LLCSimilar federal contract value in Biotech · null in contracts
  • Quince TherapeuticsSimilar federal contract value in Biotech · null in contracts
  • Eton Pharmaceuticals, Inc.Similar federal contract value in Biotech · null in contracts
  • KALA BIO, Inc.Similar federal contract value in Biotech · null in contracts
  • Provenance Group, Inc.Similar federal contract value in Biotech · null in contracts
  • HELIGENICS INCSimilar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .